Licensed providers. In-home visits in Las Vegas, North Las Vegas and Brooklyn, NY.
(718) 218-4791info@briyahealth.comA plain-language look at the only FDA-approved GHRH analog — what it was approved to treat, what the phase 3 trials and the later liver-fat study measured, how it is dosed and monitored, and what happens to the fat it removes when treatment stops.
Medically reviewed by Jonathan Paul Navar, MD, and David Kotlarsky, PA-C, with the Briya Health medical team.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, stabilized so it survives longer in the bloodstream than the natural hormone. It binds GHRH receptors in the pituitary and prompts the gland to release its own growth hormone in its normal pulsatile pattern, which in turn raises IGF-1. It is sold as Egrifta, later reformulated as Egrifta SV and Egrifta WR.
One thing specifically: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The FDA approved it on 10 November 2010, making it the first and still the only approved treatment for that condition. It is not approved for general weight loss, for body composition in people without HIV, or for anti-aging purposes, and it has not been studied in adults over 65 with HIV and lipodystrophy.
It is an abnormal redistribution of body fat seen in some people living with HIV, in which fat accumulates deep in the abdomen around the organs, and sometimes at the back of the neck, while subcutaneous fat in the face and limbs may be lost. The visceral accumulation is the clinically important part, because that depot is metabolically active and associated with cardiovascular and metabolic risk. Its causes involve both the infection itself and the effects of certain antiretroviral regimens.
In a pooled analysis of two phase 3 trials with 806 participants, tesamorelin 2 mg daily reduced visceral adipose tissue by roughly 15% relative to placebo over 26 weeks, measured by CT at the L4-L5 level. The earlier of the two trials reported a 15.2% reduction with tesamorelin against a 5.0% increase on placebo. Roughly 70% of participants met the trial definition of a visceral fat responder.
The effect is specific to visceral fat. Across both phase 3 trials, subcutaneous adipose tissue was not reduced to any clinically meaningful extent, and lean body mass did not change. That selectivity is the point of the drug in this population, since the problem being treated is deep abdominal accumulation rather than overall fat mass, and people with lipodystrophy have often already lost subcutaneous fat they would not want to lose more of.
The visceral fat comes back. In the 26-week extension phases of both trials, participants who continued tesamorelin maintained their reduction, while those switched off it re-accumulated visceral fat. This is one of the clearest findings in the tesamorelin literature and it frames the treatment as ongoing rather than a course with a finish line. It is a reasonable thing to discuss before starting, since the cost and the daily injection continue for as long as the benefit does.
As a once-daily subcutaneous injection into the abdomen, but the dose depends on which formulation you are given, and they are not interchangeable. The phase 3 trials used 2 mg daily of the original 1 mg per vial presentation. Egrifta SV is reconstituted daily. Egrifta WR, approved in March 2025, has a recommended daily dose of 1.28 mg drawn as 0.16 mL from an 11.6 mg vial, needs reconstitution only once a week, and uses less than half the injection volume. The label states explicitly that Egrifta WR and Egrifta SV are not substitutable, because they differ in strength, vial count, reconstitution steps and storage. Follow the Instructions for Use that came with your specific product rather than general guidance.
The trials measured their primary endpoint at 26 weeks, so roughly six months is the timeframe in which the studied effect was established. Prescribing practice commonly involves reassessing at around that point to determine whether a patient is responding, since about 30% of trial participants did not meet the responder definition. Continuing treatment indefinitely without a measured response is difficult to justify.
Injection site reactions are the most frequent complaint, including redness, itching, pain and swelling. Joint aches, muscle pain, swelling in the hands or feet from fluid retention, numbness or tingling, and nausea are also reported. Many of these are recognizable as effects of raising growth hormone. In the phase 3 trials, treatment-emergent serious adverse events occurred in fewer than 4% of participants over 26 weeks.
Yes, and the label reports it in detail. In the current label, anti-tesamorelin IgG antibodies were detected in about half of patients after 26 weeks and in 85% of those who had hypersensitivity reactions. About 60% of patients with antibodies showed cross-reactivity to their own natural GHRH. Reassuringly, patients with and without antibodies had similar reductions in visceral fat and similar IGF-1 responses, so the antibodies did not appear to blunt the drug's effect.
It is contraindicated in pregnancy, classified Pregnancy Category X, partly because visceral fat increases during pregnancy as a normal physiological change. It is also contraindicated in people with disruption of the hypothalamic-pituitary axis from tumor, surgery, radiation or head trauma, in those with active malignancy, and in anyone with known hypersensitivity to tesamorelin or mannitol.
The label addresses this directly. Because tesamorelin induces release of growth hormone, a known growth factor, and raises IGF-1, the benefits of treatment are meant to be weighed against the possibility of increased malignancy risk, particularly in anyone with a history of cancer. Active malignancy is a contraindication, and pre-existing cancers or precancerous conditions should be evaluated before starting. This is a caution built into the label rather than a demonstrated harm in the trials.
It can. Growth hormone opposes some of insulin's actions, so glucose intolerance and new or worsening diabetes are recognized concerns. In the phase 3 trials, average glucose measures showed no clinically meaningful difference from placebo, but among participants who started with an HbA1c below 6.5%, 5% on tesamorelin crossed that diabetes threshold by week 26 against 1% on placebo. The trials excluded people with fasting glucose of 150 mg/dL or above, and glucose is typically checked before and during treatment.
It raises it substantially. In the pooled analysis of the two phase 3 trials in people with HIV, IGF-1 rose by an average of about 108 ng/mL on tesamorelin against a small fall on placebo. A widely quoted figure of roughly a 90% rise comes from a separate 2012 trial in HIV-negative adults with abdominal obesity. IGF-1 is monitored during treatment because it is the measurable downstream marker of the growth hormone the drug is prompting, and because sustained high levels are the mechanism behind the malignancy caution.
The most specific one in the label concerns glucocorticoids. Growth hormone influences the enzyme that converts cortisone and prednisone into their active forms, so people taking glucocorticoid replacement for diagnosed adrenal insufficiency may need their maintenance or stress doses increased after starting tesamorelin. A study with simvastatin found no meaningful effect on its pharmacokinetics. Any regimen of antiretrovirals and other chronic medications should be reviewed with the prescriber.
The approval is specific to HIV-associated lipodystrophy, and the drug has not been studied for fat redistribution from other causes. Research into visceral and liver fat outside the HIV setting is ongoing, and investigators involved in the liver trial have suggested examining whether it helps HIV-negative people with liver abnormalities, but that remains a research question rather than an established use. Any use outside the approved indication is off-label and should be discussed as such.
A randomized, double-blind trial published in The Lancet HIV in 2019 tested tesamorelin 2 mg daily against placebo for 12 months in 61 people with HIV and non-alcoholic fatty liver disease. Tesamorelin reduced liver fat content and slowed progression of fibrosis. At baseline, 43% of participants already had liver fibrosis and 33% had NASH, so this was not a mild-disease population. The authors were explicit that longer studies are needed to establish effects on liver histology over time.
No. Despite the encouraging trial result, the FDA-approved indication remains reduction of excess abdominal fat in HIV-associated lipodystrophy. Investigators have suggested expanding it to cover people with HIV who have fatty liver disease, but that has not happened. Semaglutide, covered elsewhere in this Learning Center, is the GLP-1 that did receive a liver indication, for MASH with moderate to advanced fibrosis, in August 2025.
Both act on the same pituitary receptor, but they sit in very different regulatory positions. Tesamorelin is a stabilized analog of the full 44-amino-acid GHRH sequence, currently FDA-approved, with two phase 3 trials and a randomized liver trial behind it. Sermorelin is the shorter GHRH(1-29) fragment, approved in 1990 as a diagnostic agent and in 1997 for children with growth hormone deficiency, discontinued by its manufacturer in 2008, and whose adult evidence consists mostly of small studies from the 1990s. Similar mechanism, very different evidence base.
They do different jobs. GLP-1 receptor agonists such as semaglutide and tirzepatide reduce overall body weight by suppressing appetite, and their trials measured total weight loss. Tesamorelin does not suppress appetite and does not meaningfully reduce total body weight or subcutaneous fat; it selectively reduces the visceral depot. Comparing their headline percentages is misleading because the numbers describe different things: one is total body weight, the other is visceral fat volume.
This is a different situation from sermorelin. Federal law generally does not permit a compounding pharmacy to produce a copy of a commercially available FDA-approved drug, and tesamorelin is commercially available. Compounded versions marketed online should be approached with that in mind, along with the usual concerns about unverified identity, purity, sterility and potency. Questions about a specific product are worth putting to a licensed pharmacist or prescriber.
Coverage is typically tied closely to the approved indication. Insurer policies generally require documented HIV infection with lipodystrophy and excess visceral abdominal fat, and explicitly exclude fat redistribution from other causes on the grounds that the drug has not been studied in those conditions. Prior authorization is common, and continued coverage often depends on documented response.
Tesamorelin is supplied as a powder that must be reconstituted before injection, and storage and preparation differ by formulation. Egrifta SV is reconstituted daily; Egrifta WR needs reconstitution only once a week and uses a smaller injection volume. Because the handling steps are formulation-specific, the Instructions for Use supplied with your product is the authority rather than general guidance.
Visceral fat sits deep in the abdomen around the organs and behaves differently from the subcutaneous fat under the skin. It is metabolically active, releasing inflammatory signals and free fatty acids directly into the portal circulation reaching the liver, and it is more closely associated with insulin resistance, unfavorable lipids and cardiovascular risk. That is why the trials measured it by CT rather than relying on weight or waist size alone.
The trials reported improvements in trunk fat and waist circumference alongside the visceral fat reduction, and generally favorable changes in body image measures such as distress about abdominal appearance. Those were secondary findings rather than the primary endpoint. Because subcutaneous fat is largely unchanged, the visible difference is more modest than the visceral numbers alone might suggest.
A post hoc analysis of the phase 3 data looked specifically at this. The proportion of visceral fat responders was essentially identical whether or not participants had dorsocervical fat accumulation, around 68% versus 70%. In other words, having that feature did not predict a better or worse visceral fat response to the drug.
In the pooled phase 3 analysis in people with HIV, triglycerides fell by about 12% relative to placebo and the ratio of total to HDL cholesterol improved modestly. The larger figures often quoted, a roughly 20% fall in triglycerides and a 24% fall in C-reactive protein, a marker of inflammation, come from a separate 2012 trial in HIV-negative adults with abdominal obesity. Either way, these are biomarker changes rather than demonstrated reductions in heart attacks or strokes; no cardiovascular outcomes trial has been conducted for tesamorelin.
The phase 3 trials enrolled people on antiretroviral therapy, and the drug was studied in that context rather than in isolation. It is not a treatment for HIV itself and does not replace any part of an antiretroviral regimen. Any additions to a regimen should be reviewed by the clinician managing the HIV care, since that is where interactions and monitoring decisions belong.
It is not a federally controlled substance, but like other growth hormone-releasing factors and their analogs it is prohibited in competitive sport by the World Anti-Doping Agency at all times, both in and out of competition. Athletes subject to testing would need a therapeutic use exemption.
Typical monitoring includes IGF-1, since it is the measurable marker of the growth hormone being stimulated, and glucose or HbA1c, given the effects of growth hormone on insulin sensitivity. Response is assessed at around the six-month mark, in line with the trial endpoints, because continuing indefinitely without evidence of benefit is difficult to justify for a daily injection. Malignancy screening appropriate to a person's age and history belongs in that discussion too.
Worth asking: does my situation match the approved indication, and if not, what is the basis for using it off-label; how will we measure whether it is working and at what point; what happens to the benefit if I stop; what does it cost and will insurance cover it; what will be monitored and how often; and does anything in my history, particularly cancer or pituitary disease, make this inadvisable.
Growth hormone-releasing hormone is a 44-amino-acid messenger produced by the hypothalamus. It travels a short distance to the anterior pituitary and instructs it to release growth hormone, which then acts on tissues both directly and through insulin-like growth factor 1 produced by the liver. Natural GHRH is degraded quickly in the bloodstream, which makes it impractical as a medication in its native form. Tesamorelin is a synthetic version of the full-length sequence, chemically stabilized so it survives long enough to be given as a once-daily injection.
Because it acts one step upstream of growth hormone rather than supplying the hormone itself, tesamorelin works within the body's existing control system. The pituitary still releases growth hormone in its normal pulsatile pattern, and somatostatin, the hypothalamic signal that tells the pituitary to hold back, still applies its brake. The measurable downstream consequence is a substantial rise in IGF-1, averaging about 108 ng/mL above baseline in the pooled phase 3 trials, which is both the marker of the drug working and the basis for its main safety caution.
The FDA approved tesamorelin on 10 November 2010 for one purpose: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It was the first approved treatment for that condition and remains the only one. Lipodystrophy in this setting involves an abnormal redistribution of body fat, with accumulation deep in the abdomen around the organs, sometimes at the back of the neck, and often a loss of subcutaneous fat in the face and limbs. Its origins lie in both the infection itself and the metabolic effects of certain antiretroviral regimens.
The visceral component is what makes this clinically consequential rather than cosmetic. Fat in that depot releases inflammatory mediators and free fatty acids into the circulation reaching the liver, and is more closely tied to insulin resistance, unfavorable lipid profiles and cardiovascular risk than subcutaneous fat is. Narrowness of indication matters here: the drug has not been studied for fat redistribution arising from other causes, and it has not been studied in adults over 65 with HIV and lipodystrophy. Insurer coverage policies generally track that boundary closely.
Two multicenter, randomized, double-blind, placebo-controlled trials supported the approval. Both enrolled adults aged 18 to 65 with HIV, lipodystrophy and abdominal fat accumulation, defined by waist circumference and waist-to-hip ratio thresholds, with fasting glucose below 150 mg/dL. Participants received 2 mg of tesamorelin daily or placebo for 26 weeks, followed by a 26-week extension. The primary endpoint was percentage change in visceral adipose tissue measured by CT at the L4-L5 vertebral level, which is a far more precise measure than weight or waist size.
In a pooled analysis of 806 participants, visceral fat fell by approximately 15% relative to placebo at 26 weeks. The earlier trial reported a 15.2% reduction on tesamorelin against a 5.0% increase on placebo. Around 70% of participants met the trial definition of a responder, which also means roughly 30% did not. Subcutaneous fat was not reduced to a clinically meaningful extent and lean body mass did not change, so the effect was specific rather than general. Triglycerides fell by about 12% relative to placebo and the ratio of total to HDL cholesterol improved, while average glucose measures showed no clinically meaningful difference. Those are biomarker improvements; no cardiovascular outcomes trial has tested whether they translate into fewer heart attacks or strokes.
The extension phases answered the question that matters most for anyone deciding whether to start. Participants who continued tesamorelin through week 52 held onto their reduction: trunk fat was essentially unchanged between weeks 26 and 52, while placebo participants gained over the same period, and lean body mass stayed flat. Participants who came off the drug re-accumulated visceral fat. The effect depends on continued dosing, which frames tesamorelin as ongoing therapy rather than a course with an endpoint, and makes the daily injection and the cost recurring commitments rather than temporary ones. It also means the decision to stop is a decision to give back the change that was achieved.
Non-alcoholic fatty liver disease is common in people living with HIV and tends to follow a more aggressive course than in the general population, with no proven pharmacological treatment in that group. A randomized, double-blind trial run at Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases tested whether tesamorelin could change that. Sixty-one participants with HIV and a hepatic fat fraction of at least 5% received 2 mg daily or placebo for 12 months, followed by an open-label phase. Liver biopsies at baseline showed 43% already had fibrosis and 33% had NASH.
Published in The Lancet HIV in 2019, the trial found that tesamorelin reduced liver fat content and slowed progression of fibrosis over the year. Later analyses of the same paired biopsy specimens showed the drug downregulated hepatic gene sets involved in inflammation, tissue repair and cell division. The investigators were careful about what this establishes: longer studies are needed to determine effects on liver histology over time, and they suggested rather than assumed that the indication might be expanded. As of this writing it has not been. The approved use remains HIV-associated lipodystrophy alone.
Tesamorelin is contraindicated in pregnancy, classified Pregnancy Category X, partly because visceral fat increases during pregnancy as a normal physiological change. It is also contraindicated in people whose hypothalamic-pituitary axis has been disrupted by tumor, surgery, radiation or head trauma, in those with active malignancy, and in anyone with known hypersensitivity to tesamorelin or mannitol. The most common day-to-day complaints are injection site reactions, along with joint and muscle aches, fluid retention causing swelling in the hands or feet, numbness or tingling, and nausea. Serious adverse events occurred in fewer than 4% of trial participants over 26 weeks.
Two cautions follow directly from the mechanism. Because the drug induces release of growth hormone, a known growth factor, and raises IGF-1, the label instructs that benefits be weighed against a possible increase in malignancy risk, with particular attention to anyone with a history of cancer or a precancerous condition. And because growth hormone opposes some of insulin's actions, glucose intolerance and new or worsening diabetes are recognized concerns, which is why the trials excluded people with fasting glucose at or above 150 mg/dL. There is also a specific interaction worth knowing: people taking glucocorticoid replacement for diagnosed adrenal insufficiency may need their maintenance or stress doses adjusted after starting.
The label reports antibody formation in unusual detail. In the current label, anti-tesamorelin IgG antibodies were detected in about half of patients after 26 weeks, and in 85% of the subset who experienced hypersensitivity reactions. Roughly 60% of patients who developed antibodies showed cross-reactivity with their own endogenous GHRH. The clinically reassuring part is that patients with and without antibodies had similar reductions in visceral fat and similar IGF-1 responses, so antibody formation did not appear to neutralize the drug's effect.
Monitoring generally centers on IGF-1, the measurable downstream marker of the growth hormone being stimulated, and on glucose or HbA1c given the insulin sensitivity concern. Because the trials established their effect at 26 weeks and roughly 30% of participants were not responders, reassessing at around six months is a reasonable checkpoint: continuing a daily injection indefinitely without a measured response is hard to justify clinically or financially. Age-appropriate malignancy screening belongs in the same conversation, given the label's caution.
The prescribing information for the current formulation includes a table of adverse reactions from the 26-week placebo-controlled phase of the trials, in which 543 people received tesamorelin and 263 received placebo. Reading the table side by side is more informative than reading a list of possible effects, because many of the complaints people associate with the drug also occurred in the placebo group at a lower but still meaningful rate.
Injection site reactions were the clearest difference: 17% on tesamorelin against 6% on placebo, a category that combines redness, itching, rash, hives, pain, swelling, irritation and minor bleeding at the site. Joint pain was reported by 13% on tesamorelin and 11% on placebo, which is a much smaller gap than its prominence in online discussion would suggest. Muscle pain and peripheral swelling each occurred in 6% of treated participants compared with 2% on placebo, pain in an arm or leg in 6% against 5%, tingling in 5% against 2%, reduced sensation in 4% against 2%, and rash in 4% against 2%.
Several of these effects share a single cause. The label explains that fluid retention can occur during treatment and is thought to follow from the growth hormone the drug induces. Extra fluid in the tissues shows up as swelling, as stiffness and aching in joints and muscles, and occasionally as carpal tunnel syndrome, where swelling within the wrist compresses the nerve running into the hand. Carpal tunnel syndrome was uncommon in the trials, but it belongs in the same family of effects and is worth recognizing for that reason. The label describes these reactions as either transient or resolving once treatment stops.
Hypersensitivity reactions, including itching, redness, flushing, hives and rash, occurred in about 4% of treated patients across the clinical trials. The label advises stopping the drug if a hypersensitivity reaction is suspected, and it lists known hypersensitivity to tesamorelin or to mannitol, an ingredient in the product, as a reason not to use it at all. Antibody data sit alongside this: in the current label, anti-tesamorelin antibodies were detected in about half of patients at 26 weeks and in 85% of those who had a hypersensitivity reaction.
Two practical points follow from the table. First, the most common problem is local and procedural rather than systemic, which is one reason careful injection technique and site rotation matter so much. Second, joint and muscle complaints are common in adults generally, so an ache that begins during treatment is not automatically caused by it, though a pattern of swelling, stiffness and tingling appearing together is more suggestive of fluid retention and worth reporting.
Growth hormone works against some of insulin's effects, so any treatment that raises growth hormone needs to be judged partly on what it does to blood sugar. The tesamorelin data on this question look contradictory at first and make sense once you separate the average participant from the individual one.
At the level of group averages, the pooled analysis of the two phase 3 trials reported no clinically meaningful difference in glucose parameters between tesamorelin and placebo at 26 or 52 weeks. That is a reassuring finding, and it is the one most often quoted.
The label adds a detail the averages conceal. Among participants whose HbA1c started below 6.5%, the proportion who reached 6.5% or higher by week 26, which is the threshold commonly used to diagnose diabetes, was 5% on tesamorelin against 1% on placebo. The label also reports a hazard ratio of 3.3 for developing diabetes on tesamorelin compared with placebo, with a wide confidence interval of 1.4 to 9.6. Average HbA1c at the start was 5.3% in both groups, so these were not people already close to the line on average.
Put together, the two findings describe a drug that leaves most people's blood sugar essentially unchanged while tipping a minority over a diagnostic threshold. That pattern is common with metabolic drugs, and it is why a reassuring average does not remove the need to check each person. The trials also excluded anyone with fasting glucose at or above 150 mg/dL, so the data say nothing directly about people who start with poorly controlled diabetes.
The label's instructions follow from this. Glucose status should be assessed before starting, and people with diabetes should be monitored during treatment and may need their diabetes medications adjusted. The label also advises considering discontinuation in patients who develop glucose intolerance or diabetes and who do not show a clear efficacy response, which frames the decision as a balance: a meaningful visceral fat reduction may justify managing a glucose change, while a doubtful response makes that trade harder to defend.
Tesamorelin is frequently discussed alongside sermorelin, and the mechanism is genuinely similar: both act on the pituitary GHRH receptor. Their regulatory positions are not similar at all. Tesamorelin is a stabilized analog of the full 44-amino-acid sequence, currently approved, supported by two phase 3 trials and a randomized liver trial. Sermorelin is the shorter GHRH(1-29) fragment, approved in 1990 as a diagnostic agent and in 1997 for children with growth hormone deficiency, and discontinued by its manufacturer in 2008, with adult evidence consisting largely of small studies from the 1990s. Because tesamorelin is commercially available, federal rules generally prevent compounding pharmacies from producing copies of it, which is a further difference from sermorelin.
Comparisons with GLP-1 medications require more care still. Semaglutide and tirzepatide suppress appetite and reduce total body weight, and their trial headlines describe percentage of body weight lost. Tesamorelin does neither of those things: it does not act on appetite, does not meaningfully reduce total weight or subcutaneous fat, and its headline percentage describes visceral fat volume measured by CT. Placing a 15% visceral fat reduction beside a 15% body weight reduction implies an equivalence that does not exist, because the two numbers are measuring different quantities in different populations for different purposes.
Tesamorelin is often sold online in the same breath as a group of compounds described loosely as growth hormone peptides. The grouping hides real differences in how these compounds work, and much larger differences in how much is known about them.
There are two distinct routes to releasing growth hormone from the pituitary. The first is the one tesamorelin uses: the growth hormone-releasing hormone receptor, which responds to the natural hypothalamic signal. Sermorelin, a shorter fragment of that signal, uses the same receptor, as does CJC-1295, a modified analog attached to a chemical group that binds albumin in the blood so that it lingers for days rather than minutes. The second route is the ghrelin receptor, also called the growth hormone secretagogue receptor, which responds to the stomach hormone ghrelin. Compounds such as ipamorelin and the oral drug ibutamoren, also known as MK-677, act there instead.
The distinction matters because the two routes behave differently. Signals through the growth hormone-releasing hormone receptor remain subject to the somatostatin brake and tend to preserve the body's pulsatile pattern. Ghrelin-receptor compounds act on a receptor with roles beyond growth hormone, including appetite, which is why increased hunger is a recognized effect of some of them. Long-acting compounds change the picture again, since a signal that persists for days no longer resembles the natural pulse at all.
The evidence gap is the most important difference. Tesamorelin is the only compound in this group with FDA approval, two phase 3 trials and a published safety record from years of prescription use. The others have been studied mainly in small or early trials, and none is approved for any use in the United States. The FDA has also listed some of them among bulk substances that raise safety concerns when used in compounding; for ibutamoren, the agency's concerns include a potential for congestive heart failure in certain patients. The regulatory status of several peptides has been under active review, so any specific product should be checked against current FDA information rather than a seller's description.
The practical conclusion is simple. Sharing a target receptor or a general mechanism does not mean sharing an evidence base. Data from tesamorelin's trials apply to tesamorelin, at the studied dose, in the studied population, and cannot be borrowed to vouch for a different molecule.
If the goal is more growth hormone activity, the obvious question is why not inject growth hormone directly. That was tried in HIV-associated fat accumulation before tesamorelin was approved, and the results explain a good deal about why a releasing-hormone analog became the preferred approach.
Recombinant human growth hormone, marketed for HIV-associated wasting as Serostim, was tested at 4 mg daily for abdominal fat accumulation. In a double-blind trial reported in 2006, 325 people with HIV received growth hormone or placebo for 12 weeks, followed by a maintenance phase at a lower dose. Visceral fat fell by roughly a fifth on growth hormone over 12 weeks, a larger reduction than tesamorelin produces. The costs were considerable: peripheral swelling was reported by 46% and joint pain by 39% of treated participants, raised blood glucose was more common on growth hormone than placebo, at 14% against 3%, and during the maintenance phase about 40% of those who had lost visceral fat regained a significant amount of it.
Lower doses change the balance but do not remove the trade-off. A randomized trial published in JAMA in 2008 gave 56 people with HIV and abdominal fat accumulation a low, physiological dose averaging about 0.33 mg a day for 18 months. Visceral fat fell by 8.5% against 1.6% on placebo, triglycerides and diastolic blood pressure improved, and fasting glucose did not change significantly. Glucose two hours after a sugar drink, however, rose by 22 mg/dL. The investigators concluded that the window in which growth hormone delivers benefit without metabolic harm may be very narrow.
Those experiences set the context for tesamorelin. Growth hormone given directly bypasses the pituitary and its regulatory brake, produces sustained rather than pulsatile levels, and at effective doses brings substantial fluid retention and glucose effects. A releasing-hormone analog asks the pituitary to do the work, so the body's own regulation limits how far hormone levels rise. The visceral fat reduction is somewhat smaller, but the side-effect profile in the trials was considerably milder, and that trade is the core of the case for the drug.
The story begins with basic science rather than a drug program. Growth hormone-releasing hormone was characterized at the Salk Institute in the 1980s by Roger Guillemin's group, work that established the 44-amino-acid structure of the messenger the hypothalamus uses to instruct the pituitary. Identifying a hormone and turning it into a medicine are different problems, however. Native GHRH is cleaved rapidly in the bloodstream by dipeptidyl peptidase-4, the same enzyme that limits the natural GLP-1 discussed in the weight management guides on this site. A hormone that disappears within minutes of injection cannot be dosed practically, which is why the decades between characterizing GHRH and having a usable GHRH medication were spent on chemistry rather than biology.
Theratechnologies, a Montreal biopharmaceutical company, solved that problem with a specific structural modification: attaching a trans-3-hexenoic acid group to the N-terminal end of the peptide. The modification sits directly over the bond the degrading enzyme would attack, physically obstructing cleavage while leaving the part of the molecule that binds the receptor unchanged. The result is a peptide that still speaks the pituitary's language but survives long enough to be useful. It was designated TH9507 during development and later given the international nonproprietary name tesamorelin. The approach is worth understanding because it illustrates a general principle in peptide drug development: the difficulty is rarely finding a molecule that works, it is finding one that lasts.
The choice of target indication was deliberate. Rather than pursuing a broad anti-aging or body composition claim, which would have required demonstrating benefit in a large and heterogeneous population, the company aimed at HIV-associated lipodystrophy: a defined condition, in an identifiable population, with a measurable endpoint and no existing treatment. Phase 2 dose-ranging work established that 2 mg daily by subcutaneous injection produced the best balance of visceral fat reduction and tolerability. Notably, higher doses did not meaningfully improve results, which is consistent with how the mechanism works. Because the drug asks the pituitary to release its own growth hormone rather than supplying hormone directly, the gland's own regulatory ceiling limits how much additional effect more drug can produce.
That self-limiting quality is the strongest argument in favor of secretagogues generally, and it is worth separating from the marketing that surrounds them. It does not mean a GHRH analog cannot cause harm, and it does not mean the resulting hormone levels are automatically physiological. It means the dose-response relationship flattens out, so escalating the dose is unlikely to produce proportionally larger effects. Tesamorelin is the only GHRH analog to have carried this reasoning through a full development program to approval, which is what separates it from the other peptides commonly marketed alongside it.
Tesamorelin has been sold in three forms since 2010, and the differences between them are practical rather than pharmacological. The original Egrifta, approved in November 2010, required a two-vial preparation reconstituted daily. In May 2019 the FDA cleared Egrifta SV, a more concentrated single-vial formulation that reduced the daily preparation burden. In March 2025 the FDA approved Egrifta WR, the F8 formulation, which shifts reconstitution from daily to weekly and requires less than half the injection volume of its predecessor. Theratechnologies designed the change explicitly to reduce the burden of a medication that is taken every day indefinitely.
The most important thing to know about these formulations is that they are not interchangeable. The label states plainly that Egrifta WR and Egrifta SV are not substitutable, because they differ in strength, in the number of vials needed to prepare a dose, in reconstitution instructions and in storage requirements. The doses themselves differ: the recommended daily dose of Egrifta WR is 1.28 mg, drawn as 0.16 mL from an 11.6 mg vial, whereas the earlier formulations used a 2 mg daily dose from a 2 mg per vial presentation. Anyone transitioning between formulations needs instructions specific to the one they have been dispensed, and applying the old routine to the new product would be an error.
Availability has not always been smooth. In April 2025 the FDA approved a supplemental application that removed a regulatory requirement for discretionary product release, allowing the manufacturer to resume normal distribution of Egrifta SV after a period of supply uncertainty. Egrifta WR became available through specialty pharmacies in September 2025, and Egrifta SV was expected to remain available during a transitional period while insurers extended coverage to the newer formulation. For a medication supplied through specialty HIV care channels rather than ordinary retail pharmacies, these logistics matter as much to a patient as the clinical data does.
The reformulation history also explains why older sources, including much of the published trial literature, describe a 2 mg daily dose. Those studies used the original formulation, and the newer product delivers a bioequivalent exposure at a different labeled dose. This is a common source of confusion when comparing a trial publication against a current prescription, and it is one reason the Instructions for Use supplied with a specific product, rather than a general description found online, is the authority on how to prepare and inject it.
The phase 3 trials measured their primary endpoint as percentage change in visceral adipose tissue on computed tomography at the L4-L5 vertebral level. That choice deserves explanation, because it is the reason the results can be trusted in a way that many body composition claims cannot. A single CT slice at a standardized anatomical landmark distinguishes visceral fat, which lies inside the abdominal wall around the organs, from subcutaneous fat, which lies outside it. No amount of weighing, measuring or photographing can make that distinction, and the two compartments behave differently enough that conflating them produces meaningless results.
This matters for interpreting the trial outcome correctly. Tesamorelin reduced the visceral compartment by roughly 15% relative to placebo while leaving the subcutaneous compartment and lean mass essentially unchanged. A scale would have registered very little. A tape measure would have registered something, since waist circumference did improve, but far less dramatically than the visceral figure suggests. Only the imaging endpoint captures what actually happened. When a treatment claims to target a specific fat compartment, the question worth asking is how that compartment was measured, and a claim resting on scale weight or photographs is not answering it.
Other methods exist and have their own trade-offs. Dual-energy X-ray absorptiometry is widely available and good at separating fat mass from lean mass, but it is less precise at distinguishing visceral from subcutaneous fat. Magnetic resonance imaging avoids the radiation exposure of CT and can quantify liver fat as well, which is why the later liver trial used proton magnetic resonance spectroscopy for its hepatic fat fraction measurements. Waist circumference and waist-to-hip ratio are free and repeatable, which is why the trials used them as entry criteria, but they are screening tools rather than precise measures of a specific depot.
In ordinary clinical practice, repeated CT scanning to track a patient's response is rarely justified, given cost and cumulative radiation exposure. That creates a practical gap between how the drug was studied and how its effect is followed in real use, where clinicians generally rely on waist measurements, weight trends, IGF-1 levels and clinical judgment. It is a reasonable approach, but it means an individual patient's visceral fat change is usually estimated rather than measured with the precision the trials achieved.
Tesamorelin acts fast and clears fast. After a subcutaneous injection, peak plasma concentration arrives at about nine minutes, and the drug is gone from the bloodstream shortly afterward. That seems counterintuitive for a medication taken once daily, until you consider what it is actually doing. It is not meant to stay in circulation; it is meant to deliver a signal to the pituitary, which then releases growth hormone in a pulse. The pulse and its downstream effects outlast the drug itself by a wide margin.
This is the clearest practical difference between a secretagogue and growth hormone itself. Injected growth hormone circulates for hours and produces a sustained, non-pulsatile level. Tesamorelin produces a brief prompt, after which the body's own regulatory machinery, including the somatostatin brake, determines how much hormone is released and for how long. The IGF-1 rise that follows is the durable signal: it persists through the day and is what laboratory monitoring actually measures, since the growth hormone pulse itself would be almost impossible to capture with a random blood draw.
The label notes something interesting about the population it was studied in: overall drug exposure was about 34% higher in people with HIV than in healthy volunteers, while peak concentration was similar. Differences of this kind are common when a drug is studied in a population with altered body composition, liver handling or concurrent medications, and they are one reason data from one group cannot be assumed to transfer cleanly to another. It is also part of why using the drug outside the studied population means reasoning by analogy rather than from evidence.
Timing follows from the biology. The body's largest natural growth hormone pulse occurs during early deep sleep, and elevated blood sugar and insulin blunt release, so an injection given in the evening works with that rhythm rather than against it. Drug interaction testing has been limited but specific: co-administration with simvastatin, a drug processed by the CYP3A pathway, produced no meaningful change in simvastatin levels, which is reassuring for a population often taking several long-term medications.
HIV-associated lipodystrophy emerged as a recognized problem in the era of effective antiretroviral therapy. As treatment transformed HIV from a fatal illness into a manageable chronic condition, clinicians began seeing a pattern of body composition change: fat accumulating deep in the abdomen and sometimes at the back of the neck, while subcutaneous fat was lost from the face, arms and legs. Both the infection itself and the metabolic effects of certain antiretroviral regimens are thought to contribute, and newer regimens are generally considered less likely to provoke it than some older ones.
Calling it a cosmetic problem understates it in one direction and overstates it in another. The visceral accumulation carries genuine metabolic consequences, contributing to insulin resistance, unfavorable lipid profiles and cardiovascular risk in a population that is now living long enough for those risks to matter. At the same time, the visible changes can be distressing and stigmatizing in ways that affect whether people stay engaged with their care at all. The trials measured both dimensions, reporting body image outcomes alongside the imaging endpoints.
This context explains the shape of tesamorelin's development. A drug that selectively reduced visceral fat without touching subcutaneous fat would be an odd goal in the general population, where subcutaneous fat loss is usually what people are seeking. In lipodystrophy it is precisely the right goal, because many patients have already lost subcutaneous fat they would rather keep. The selectivity that makes tesamorelin useful here is the same property that makes it a poor fit for general weight management, and the label says directly that it is not indicated for weight loss.
Liver disease has become part of the same picture. Fatty liver disease is common among people living with HIV and tends to follow a more aggressive course than in the general population, which is why the later liver trial was conducted in that group specifically. Visceral fat and liver fat are related but distinct problems, and a drug that addresses both is of particular interest in a population carrying elevated risk of each.
Tesamorelin was developed for a pattern of body change most closely associated with older antiretroviral regimens: fat lost from the face and limbs while it accumulated deep in the abdomen. That classic lipodystrophy is seen less often with modern treatment. A different problem has taken much of its place, and understanding it helps place tesamorelin correctly.
The newer concern is weight gain after starting treatment, particularly with regimens that combine an integrase inhibitor such as dolutegravir with tenofovir alafenamide. The clearest evidence comes from the ADVANCE trial in South Africa, which randomized 1,053 people starting treatment, most of them young Black women, to one of three regimens. At 96 weeks, women on dolutegravir with tenofovir alafenamide had gained an average of 8.2 kg, compared with 4.6 kg on dolutegravir with the older tenofovir formulation and 3.4 kg on an efavirenz-based regimen. Men gained less on each regimen, at 5.2, 3.6 and 1.4 kg respectively.
The composition of that weight gain differs from classic lipodystrophy. In ADVANCE it was mostly fat rather than lean tissue and was distributed across both the trunk and the limbs, rather than concentrated in the abdomen while the limbs thinned. Investigators also noted no sign of a plateau at 96 weeks, which is part of why the finding drew so much attention.
This shift matters for how tesamorelin fits into current care. It is a treatment for excess visceral fat, and its trials enrolled people with HIV-associated lipodystrophy and abdominal fat accumulation. Generalized weight gain spread across the body is a different problem, and a drug that selectively reduces visceral fat while leaving total weight and subcutaneous fat largely unchanged is not designed to address it. For that pattern, attention has turned to the same approaches used for weight management generally, including the GLP-1 medications discussed elsewhere in this Learning Center.
None of this makes the older problem disappear. Many people living with HIV started treatment on older regimens and carry the body composition changes that resulted, and visceral fat accumulation still occurs. It does mean that a person with HIV concerned about weight or body shape may be dealing with a different problem than the one tesamorelin was built for, and identifying which one is the first step.
Tesamorelin is the only drug approved specifically for excess visceral fat in HIV-associated lipodystrophy, but it has never been the only tool clinicians have used. Knowing what else has been tried helps put its role in proportion.
Metformin was studied early. A small randomized trial published in JAMA in 2000 gave 26 people with HIV lipodystrophy and insulin resistance either 500 mg of metformin twice daily or placebo for three months. Metformin lowered insulin levels by about a fifth, reduced weight by an average of 1.3 kg against a small gain on placebo, and lowered diastolic blood pressure. Visceral fat fell on metformin while rising on placebo, but the difference did not quite reach statistical significance in a trial of that size. Diarrhea, mostly mild to moderate and settling within weeks, affected nearly two-thirds of those taking it. Metformin addresses insulin resistance more reliably than visceral fat, which is a useful distinction when the two problems coexist.
GLP-1 medications are now being studied in people living with HIV. In the SLIM LIVER study, a single-arm pilot of 51 adults with HIV and fatty liver disease in the United States and Brazil, weekly semaglutide titrated to 1.0 mg for 24 weeks reduced liver fat by an average of about 31% in relative terms, and 29% of participants no longer met the threshold for fatty liver disease. Median weight loss was 7.8 kg. The study had no placebo group, so it establishes feasibility rather than proving the effect, but it points in the same direction as the much larger trials of these drugs in the general population.
Lifestyle measures remain the foundation for everyone. Regular physical activity, particularly a combination of aerobic and resistance exercise, reduces visceral fat and improves insulin sensitivity without any of the risks attached to drugs, and dietary change supports the same goals. Reviewing the antiretroviral regimen is also part of the conversation, since some older drugs were more strongly associated with fat redistribution than their replacements, though any change to HIV treatment belongs with the clinician managing it.
These options are not interchangeable, because they target different things. Tesamorelin selectively reduces visceral fat without meaningful weight loss. GLP-1 medications reduce total weight and liver fat substantially. Metformin chiefly improves insulin resistance. The right choice depends on which problem is actually present, which is why an accurate description of the problem comes before any choice of treatment.
Tesamorelin has been studied outside its approved indication, and the most substantial of that work concerns cognition. A randomized, double-blind, placebo-controlled trial led by Laura Baker, published in Archives of Neurology in 2012, gave 1 mg daily or placebo to 152 adults aged 55 to 87 for 20 weeks, half an hour before bedtime. The group included both cognitively healthy older adults and people with amnestic mild cognitive impairment, the stage that often precedes Alzheimer's dementia. The rationale was straightforward: growth hormone and IGF-1 decline with age and have documented effects on brain function, and a GHRH analog offers a relatively clean way to test whether restoring them helps.
The trial reported improvement in executive function, the cluster of abilities covering planning, focus and selective attention, in both healthy participants and those with mild cognitive impairment, with a smaller effect on verbal memory. A companion analysis published in JAMA Neurology in 2013 found changes in brain chemistry consistent with the cognitive findings. These are genuinely interesting results. They are also a single trial of 20 weeks, and the investigators themselves called for larger and longer studies to establish whether any of this translates into meaningful clinical benefit.
Replication has not been straightforward. A small pilot published in 2026 tested low-dose tesamorelin over 10 weeks in 22 people with cognition ranging from normal to mildly impaired, and found no significant changes across its measures of cognition, body composition, sleep, glucose tolerance or brain connectivity. A null result in 22 people over 10 weeks does not refute a positive result in 152 people over 20 weeks, but it does illustrate why a single encouraging trial is a starting point rather than a conclusion, and why the cognitive use remains investigational rather than approved.
The liver research follows a similar pattern of promise and open questions. Follow-up analyses of the biopsy specimens from the 2019 trial showed that tesamorelin downregulated hepatic gene sets involved in inflammation, tissue repair and cell division, and a related study examined corresponding changes in circulating proteins. Investigators have suggested studying whether the same effects occur in people without HIV. None of that work has produced an approved indication, and describing any of it as established use would misrepresent where the evidence stands.
The most substantial trial of tesamorelin outside HIV was published in The Journal of Clinical Endocrinology & Metabolism in 2012. It tested a specific idea: that people with abdominal obesity often have blunted growth hormone secretion, and that restoring it might reduce visceral fat and improve cardiovascular risk markers even without HIV.
The trial randomized 60 adults with abdominal obesity and reduced growth hormone secretion to tesamorelin 2 mg daily or placebo for 12 months, double-blind. Visceral fat fell significantly compared with placebo, as did waist circumference, trunk fat and total fat, while lean body mass increased. IGF-1 rose by about 90%, triglycerides fell by about 20%, and C-reactive protein, a marker of inflammation, fell by about 24%. Carotid intima-media thickness, an ultrasound measure of the artery wall used as a marker of cardiovascular risk, also decreased compared with placebo. Subcutaneous abdominal fat, total body weight and cholesterol levels did not change significantly.
These are the figures most often attached to tesamorelin in online discussion, and it is worth being precise about where they came from. They describe HIV-negative adults selected partly because their growth hormone secretion was already reduced, not the HIV lipodystrophy population in which the drug is approved. The phase 3 trials in HIV reported their own figures, which differ: in the pooled analysis, IGF-1 rose by about 108 ng/mL against a small fall on placebo, and triglycerides fell by about 12% relative to placebo.
The 2012 findings are promising and have clear limits. Sixty participants over one year is a small trial, and every outcome measured was a marker of risk rather than a cardiovascular event. The authors themselves called for further work to establish the clinical meaning of the artery wall changes. Selecting participants with reduced growth hormone secretion also means the result may not apply to people with normal secretion, who would have less deficit to correct.
No regulatory approval has followed for this population, so tesamorelin used for abdominal obesity without HIV remains off-label. The trial is best read as evidence that the mechanism works outside HIV in a defined group, and as a reason for larger studies, rather than as support for general use as a body composition treatment.
IGF-1 is the laboratory number that shows tesamorelin is doing what it is designed to do, and the label uses it to set boundaries as well as to confirm a response. Understanding how it is reported makes those boundaries easier to follow.
Because normal IGF-1 falls with age and differs between men and women, results are often expressed as a standard deviation score, abbreviated SDS, which compares a person's level with the typical range for their age and sex. A score of 0 sits in the middle of that range, and a score above 2 means the level is higher than roughly 97 or 98 of every 100 comparable people.
The label reports how often scores rose into those upper regions. During the first 26 weeks, 47% of treated patients had an IGF-1 above 2 SDS at some point, and 36% above 3 SDS. Among those who continued to week 52, the corresponding figures were 34% and 23%. In other words, a substantial minority of people on the approved dose reach IGF-1 levels well above the normal range for their age.
That matters because IGF-1 is also the basis for the drug's main precaution. It promotes cell growth and inhibits programmed cell death, which is why sustained high levels underlie the label's caution about malignancy. The label therefore advises considering discontinuation in patients with persistent IGF-1 elevations, giving more than 3 SDS as an example, particularly when the efficacy response is not robust.
The label sets out three situations in which stopping deserves consideration: persistently high IGF-1 without a strong response; development of glucose intolerance or diabetes without a clear efficacy response; and absence of a clear reduction in visceral fat. What links them is a comparison between benefit and cost. A good visceral fat response can justify accepting a manageable downside, while a weak response makes any downside harder to accept. Agreeing in advance on how response will be judged, and at what point, turns that comparison from an impression into a decision.
Tesamorelin occupies an unusual position in peptide marketing. Because it is genuinely FDA-approved, its name lends credibility to pages selling things that are not, and its trial data gets quoted in contexts the trials never covered. A few habits make those claims easier to evaluate. The first is to ask which population was studied. Every efficacy figure on this page comes from adults with HIV and lipodystrophy, and none of it establishes what happens in someone without that condition.
The second is to ask what was measured. A 15% reduction in visceral fat on CT and a 15% reduction in total body weight are entirely different claims, and seeing them presented side by side is a reliable sign that a page is optimizing for impression rather than accuracy. Tesamorelin did not meaningfully change total body weight in its trials, and the label states it is not indicated for weight loss. Any page implying otherwise is describing something the evidence does not show.
The third is to notice when a biomarker is standing in for an outcome, and which study a number came from. In the phase 3 trials, triglycerides fell by about 12% relative to placebo; the larger falls often quoted, around 20% for triglycerides and 24% for C-reactive protein, come from a separate trial in HIV-negative adults with abdominal obesity. Those are real measurements and plausibly meaningful, but no cardiovascular outcomes trial has tested whether tesamorelin prevents heart attacks or strokes, and the label states that long-term cardiovascular safety has not been established. Semaglutide, by contrast, has a trial that counted actual cardiovascular events. Knowing which kind of evidence supports a claim is the difference between an informed decision and an impression.
The fourth is to check what is being sold. Tesamorelin is commercially available as an approved product, and federal rules generally prohibit compounding pharmacies from producing copies of commercially available approved drugs. A site offering compounded tesamorelin, or bundling it with peptides that cannot lawfully be compounded at all, is telling you something about its regard for those rules. The credibility that comes from an FDA approval belongs to the approved product used as labeled, and it does not transfer to whatever is being sold alongside it.
Being clear about the limits of the evidence is part of describing it accurately. The label itself states that long-term cardiovascular safety has not been established, which is a meaningful gap for a drug intended to be taken indefinitely in a population with elevated cardiovascular risk. The improvements in triglycerides and inflammatory markers point in a favorable direction, but pointing in a direction is not the same as demonstrating that events are prevented.
Several practical questions also lack answers. There is no information on use in people over 65 with HIV and lipodystrophy, because the trials enrolled adults aged 18 to 65. There are no data supporting improved adherence to antiretroviral therapy as a result of treatment, something the label notes explicitly. And while the trials ran to 52 weeks with extension phases, they do not tell us what happens over five or ten years of continuous use, which is the timeframe that matters for a therapy without a natural endpoint.
The malignancy question sits in a similar place. The concern is mechanistic rather than observed: growth hormone is a growth factor and IGF-1 promotes cell growth while inhibiting programmed cell death, so the label instructs that benefits be weighed against a possible increase in risk. No trial has demonstrated that tesamorelin causes cancer, and no trial has been large enough or long enough to exclude a small effect. Both of those statements are true simultaneously, and anyone presenting only one of them is not giving you the full picture.
Finally, the responder question deserves more attention than it usually gets. Roughly 30% of trial participants did not meet the definition of a visceral fat responder, and no reliable way to predict in advance who will respond has been established. The post hoc analysis of dorsocervical fat found that this visible feature did not predict response either way. In practice that means starting treatment is partly an experiment, which is a strong argument for defining in advance how response will be judged and at what point.
A daily injection that must be reconstituted, stored correctly and continued indefinitely is a real commitment, and the practical side of treatment deserves as much thought as the clinical side. The drug is supplied as a powder requiring mixing before use, with the steps depending on which formulation has been dispensed. The newer weekly-reconstitution product exists specifically because the daily mixing routine of its predecessor was a barrier, which is a reasonable indicator of how much that burden affected people in practice.
Injection site reactions are the most commonly reported adverse effects, including redness, itching, pain and swelling, and they are a frequent reason people find the routine difficult. Rotating injection sites across the abdomen is standard advice. Because the injection is given daily rather than weekly, small problems with technique or site selection compound quickly, which is why the label directs that a healthcare provider demonstrate the mixing and injection process before the first dose rather than leaving it to written instructions alone.
Access runs through specialty pharmacy channels rather than ordinary retail, and insurer coverage is typically tied tightly to the approved indication. Policies generally require documented HIV infection with lipodystrophy and excess visceral abdominal fat, exclude fat redistribution from other causes on the grounds that the drug has not been studied there, and often require prior authorization with continued coverage contingent on documented response. Understanding those requirements before starting avoids an interruption partway through a course of treatment that only works while it continues.
The monitoring schedule adds its own rhythm: IGF-1 to track the hormonal response, glucose or HbA1c given the effects on insulin sensitivity, and a considered assessment of response at around the six-month mark in line with the trial endpoints. None of this is onerous individually, but taken together it makes tesamorelin a therapy that involves ongoing engagement with a care team rather than a prescription that can be collected and forgotten about.
This guide draws on FDA prescribing information, peer-reviewed clinical trial publications and regulatory announcements. It is provided for general education and does not constitute medical advice. Speak with a licensed healthcare provider about any medication or treatment decision.